Core Scientific (CORZW) Current Deferred Revenue (2021 - 2026)

Core Scientific has reported Current Deferred Revenue for 6 years, with the latest figure at $287.2 million in Q2 2026.

• Quarterly Current Deferred Revenue rose 91.31% year-over-year to $287.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $287.2 million (up 91.31% YoY) and the FY2025 annual result came in at $127.6 million, up 603.44% from the prior year.
• Current Deferred Revenue declined to $287.2 million in Q2 2026 per CORZW's latest filing, from $654.2 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $654.2 million in Q1 2026 and troughed at $7.9 million in Q2 2024.
• A 5-year average of $117.3 million and a median of $82.0 million in 2022 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue tumbled 93.23% in 2024, then soared 1797.46% in 2025.
• Over 5 years, Current Deferred Revenue stood at $77.7 million in 2022, then slumped by 87.35% to $9.8 million in 2023, then jumped by 84.48% to $18.1 million in 2024, then jumped by 603.44% to $127.6 million in 2025, then surged by 125.15% to $287.2 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $287.2 million, $654.2 million, and $127.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.